{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:32:41Z","timestamp":1773030761631,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"onselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico"},{"DOI":"10.13039\/501100006162","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Ci\u00eancia e Tecnologia do Estado de Pernambuco","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006162","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Instituto Nacional de Ci\u00eancia e Tecnologia para Inova\u00e7\u00e3o Farmac\u00eautica"},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.imbio.2020.151964","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T12:15:04Z","timestamp":1590149704000},"page":"151964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Increased levels of the soluble oncostatin M receptor (sOSMR) and glycoprotein 130 (sgp130) in systemic sclerosis patients and associations with clinical parameters"],"prefix":"10.1016","volume":"225","author":[{"given":"Anderson Rodrigues","family":"de Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a Tavares","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelly Cristiny","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moacyr Jesus Barreto","family":"de Melo R\u00eago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela Silva","family":"Guimar\u00e3es Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan da Rocha","family":"Pitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Luzia","family":"Branco Pinto Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulcineia Saes","family":"Parra Abdalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira Galdino","family":"da Rocha Pitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2020.151964_bib0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic-sclerosis (Scleroderma)","volume":"23","author":"[Anon]","year":"1980","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imbio.2020.151964_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.14153","article-title":"Systemic sclerosis","author":"Asano","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/path.2361","article-title":"Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas","author":"Chen","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.imbio.2020.151964_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4312","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials","volume":"15","author":"Choy","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imbio.2020.151964_bib0025","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0030","series-title":"How Does Methotrexate Suppress Inflammation?","first-page":"8","author":"Cronstein","year":"2010"},{"key":"10.1016\/j.imbio.2020.151964_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.imlet.2018.03.011","article-title":"Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations","volume":"198","author":"Dantas","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.imbio.2020.151964_bib0040","first-page":"165","article-title":"Evaluation and management of esophageal manifestations in systemic sclerosis","volume":"31","author":"Denaxas","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"10.1016\/j.imbio.2020.151964_bib0045","doi-asserted-by":"crossref","first-page":"36673","DOI":"10.1074\/jbc.M607005200","article-title":"Molecular and functional characterization of a soluble form of Oncostatin M\/Interleukin-31 shared receptor * \u25a1","volume":"281","author":"Diveu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.imbio.2020.151964_bib0050","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3389\/fimmu.2018.01865","article-title":"Interleukin-6 and Type-I collagen production by systemic sclerosis fibroblasts are differentially regulated by Interleukin-17A in the presence of transforming growth factor-beta 1","volume":"9","author":"Dufour","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2020.151964_bib0055","first-page":"1","article-title":"Oncostatin M as a potential molecular target in systemic sclerosis","volume":"67","author":"Feeney","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0060","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.4049\/jimmunol.176.7.4352","article-title":"Oncostatin-m up-regulates VCAM-1 and synergizes with IL-4 in eotaxin expression: involvement of STAT6","volume":"176","author":"Fritz","year":"2006","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.imbio.2020.151964_bib0065","first-page":"328","article-title":"Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis","volume":"24","author":"Hasegawa","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0070","first-page":"308","article-title":"Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis","volume":"25","author":"Hasegawa","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0075","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/rheumatology\/38.7.612","article-title":"Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis","volume":"38","author":"Hasegawa","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.imbio.2020.151964_bib0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2249.1999.00929.x","article-title":"Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibros","volume":"117","author":"Hasegawa","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imbio.2020.151964_bib0085","first-page":"1","article-title":"Oncostatin M induces RIG-I and MDA5 expression and enhances the double-stranded RNA response in fibroblasts Cell culture","volume":"XX","author":"Hergovits","year":"2017","journal-title":"Reagents Recombinant Cytokines"},{"key":"10.1016\/j.imbio.2020.151964_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2015.07.006","article-title":"Cytokine & Growth Factor Reviews Oncostatin M and interleukin-31\u202f: Cytokines, receptors, signal transduction and physiology","author":"Hermanns","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.imbio.2020.151964_bib0095","first-page":"10","article-title":"Digital ulcers in systemic sclerosis are associated with microangiopathic abnormalities of peri-lesional skin as assessed by capillaroscopy","volume":"9742","author":"Hughes","year":"2016","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0100","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.4049\/jimmunol.165.4.2149","article-title":"Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway","volume":"165","author":"Ihn","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2020.151964_bib0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13402-011-0011-2","article-title":"Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma","volume":"34","author":"Kausar","year":"2011","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.imbio.2020.151964_bib0110","series-title":"Bronchoalveolar Lavage Proteomic Analysis in Pulmonary Fibrosis Associated With Systemic Sclerosis\u202f: S100A6 and 14-3-3 E As Potential Biomarkers","first-page":"165","author":"Landi","year":"2019"},{"key":"10.1016\/j.imbio.2020.151964_bib0115","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cytogfr.2015.12.002","article-title":"New insights into CD4+T cell abnormalities in systemic sclerosis","volume":"28","author":"Liu","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.imbio.2020.151964_bib0125","first-page":"1","article-title":"Anti-OSM antibody inhibits tubulointerstitial lesion in a murine model of lupus nephritis","volume":"2017","author":"Liu","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"11","key":"10.1016\/j.imbio.2020.151964_bib0130","article-title":"Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis","volume":"35","author":"Low","year":"2008","journal-title":"J. Rheumatol. Rheumatol. Relat. Field"},{"key":"10.1016\/j.imbio.2020.151964_bib0135","series-title":"Review\u202f: the Roles and Mechanisms of Glycoprotein 130 Cytokines in the Regulation of Adipocyte Biological Function","author":"Ma","year":"2019"},{"key":"10.1016\/j.imbio.2020.151964_bib0140","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9632846","article-title":"Protective effects of methotrexate against proatherosclerotic cytokines: a review of the evidence","volume":"2017","author":"Mangoni","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.imbio.2020.151964_bib0145","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29421","article-title":"Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice","author":"Matsuda","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.imbio.2020.151964_bib0150","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7908793","article-title":"Th1-and Th17-Related cytokines in venous and arterial blood of sclerodermic patients with and without digital ulcers","volume":"2019","author":"Nicola","year":"2019","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.imbio.2020.151964_bib0155","first-page":"1","article-title":"GP130 cytokines in breast Cancer and bone","volume":"6","author":"Omokehinde","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.imbio.2020.151964_bib0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","author":"Pattanaik","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2020.151964_bib0165","article-title":"Determinants of mortality in systemic sclerosis: a focused review","author":"Ram","year":"2017","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.imbio.2020.151964_bib0170","first-page":"1","article-title":"The enigmatic cytokine oncostatin m and roles in disease","volume":"2013","author":"Richards","year":"2013","journal-title":"ISRN Inflamm."},{"key":"10.1016\/j.imbio.2020.151964_bib0175","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7040095","article-title":"Oncostatin M in the regulation of connective tissue cells and macrophages in pulmonary disease","volume":"7","author":"Richards","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.imbio.2020.151964_bib0180","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.imbio.2020.151964_bib0185","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/317503","article-title":"Oncostatin M and TLR-4 ligand synergize to induce MCP-1, IL-6, and VEGF in human aortic adventitial fibroblasts and smooth muscle cells","volume":"2013","author":"Schnittker","year":"2013","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.imbio.2020.151964_bib0190","first-page":"1","article-title":"Oncostatin M and its role in fibrosis","volume":"0","author":"Stawski","year":"2018","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.imbio.2020.151964_bib0195","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/art.40455","article-title":"Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"70","author":"Stifano","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.imbio.2020.151964_bib0200","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-4632.2007.02887.x","article-title":"Evaluation of oral methotrexate in the treatment of systemic sclerosis","volume":"46","author":"Sumanth","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0695-1","article-title":"Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures","volume":"17","author":"Taroni","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imbio.2020.151964_bib0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2017.05.013","article-title":"Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis","volume":"184","author":"Ugor","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.imbio.2020.151964_bib0215","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"Van Den Hoogen","year":"1996","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.imbio.2020.151964_bib0220","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1161\/01.ATV.19.8.1835","article-title":"Oncostatin m induces angiogenesis in vitro and in vivo","volume":"19","author":"Vasse","year":"1999","journal-title":"Arter. Thromb Vasc Biol."},{"key":"10.1016\/j.imbio.2020.151964_bib0225","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/14728222.2019.1677608","article-title":"Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)","volume":"23","author":"Verstockt","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.imbio.2020.151964_bib0230","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor\u2013neutralizing therapy in patients with inflammatory bowel disease","author":"West","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.imbio.2020.151964_bib0235","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12694","article-title":"The oncostatin M-stromal cell axis in health and disease","volume":"88","author":"West","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.imbio.2020.151964_bib0240","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ard.2009.121053","article-title":"Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation","volume":"70","author":"Yoshizaki","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imbio.2020.151964_bib0245","first-page":"716","article-title":"[Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms]","volume":"51","author":"Zhu","year":"2019","journal-title":"Beijing Da Xue Xue Bao"}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298519303821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298519303821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:47:01Z","timestamp":1759250821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298519303821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0171298519303821"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2020.151964","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased levels of the soluble oncostatin M receptor (sOSMR) and glycoprotein 130 (sgp130) in systemic sclerosis patients and associations with clinical parameters","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2020.151964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"151964"}}